Answer
Durvalumab (Imfinzi) is contraindicated in patients with hypersensitivity to durvalumab or any excipient listed in section 6.1 of its product information.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusionAstraZeneca UK Limited · emc · SmPC §4.3 Contraindications · Version 38Document updated
Sources checked